浏览全部资源
扫码关注微信
江西中医药大学现代中药制剂教育部重点实验室,南昌 330004
Published:15 November 2023,
Received:03 April 2023,
Revised:14 October 2023,
扫 描 看 全 文
黄慧辰,钟萍,张海燕.模型引导的药物研发在中药中的应用优势和进展 Δ[J].中国药房,2023,34(21):2658-2664.
HUANG Huichen,ZHONG Ping,ZHANG Haiyan.Advantage and progress of model-induced drug development in traditional Chinese medicine[J].ZHONGGUO YAOFANG,2023,34(21):2658-2664.
黄慧辰,钟萍,张海燕.模型引导的药物研发在中药中的应用优势和进展 Δ[J].中国药房,2023,34(21):2658-2664. DOI: 10.6039/j.issn.1001-0408.2023.21.16.
HUANG Huichen,ZHONG Ping,ZHANG Haiyan.Advantage and progress of model-induced drug development in traditional Chinese medicine[J].ZHONGGUO YAOFANG,2023,34(21):2658-2664. DOI: 10.6039/j.issn.1001-0408.2023.21.16.
模型引导的药物研发(MIDD)是一种用于构建、验证和利用疾病模型、药物暴露反应模型和药学模型来促进药物开发的数学和统计方法。随着制药技术的发展,MIDD在中药领域应用广泛,具有较高的实用价值。本文总结了国内外相关文献,发现MIDD具有提高中药研发效率、快速明确中药的适用人群、预测药物的交互作用、优化给药剂量等优势,且在中药药效成分、组方定量设计、剂型和制剂工艺、中试放大、质量与安全性、监管决策与评价等研究方面均有应用。
Model-induced drug development (MIDD) is a mathematical and statistical method for constructing, validating and utilizing disease model, drug exposure-response model and pharmaceutical model to promote drug development. With the development of pharmaceutical technology, MIDD is widely used in the field of traditional Chinese medicine and has high practical value. This article summarizes the relevant literature at home and abroad, and finds that MIDD has the advantages of improving the research and development efficiency of traditional Chinese medicine, quickly identifying the applicable population of traditional Chinese medicine, predicting the interaction of drugs, and optimizing the dosage. MIDD has been applied in the studies of effective components of traditional Chinese medicine, quantitative design of prescription, dosage form and preparation process, pilot scale-up, quality and safety, regulatory decision-making and evaluation, etc.
模型引导的药物研发中药应用优势应用进展
traditional Chinese medicineapplication advantageapplication advance
国家药品监督管理局药品审评中心.模型引导的药物研发技术指导原则[EB/OL].(2020-12-31)[2023-08-04].https://www.cde.org.cn/main/news/viewInfoCommon/23b634adf79ecd4616bb91bcd66815f0https://www.cde.org.cn/main/news/viewInfoCommon/23b634adf79ecd4616bb91bcd66815f0.
Center for Drug Evaluation,NMPA. Model-informed technical guidelines for drug development[EB/OL].(2020-10-31)[2023-08-04]. https://www.cde.org.cn/main/news/viewInfoCommon/23b634adf79ecd4616bb91bcd66815f0https://www.cde.org.cn/main/news/viewInfoCommon/23b634adf79ecd4616bb91bcd66815f0.
焦正,李新刚,尚德为,等. 模型引导的精准用药:中国专家共识:2021版[J]. 中国临床药理学与治疗学,2021,26(11):1215-1228.
JIAO Z,LI X G,SHANG D W,et al. Model informed precision dosing:China expert consensus report:2021 edition [J]. Chin J Clin Pharmacol Ther,2021,26(11):1215-1228.
刘东阳,王鲲,马广立,等. 新药研发中定量药理学研究的价值及其一般考虑[J]. 中国临床药理学与治疗学,2018,23(9):961-973.
LIU D Y,WANG K,MA G L,et al. The value and general consideration of pharmacometric study in new drug deve- lopment[J]. Chin J Clin Pharmacol Ther,2018,23(9):961-973.
EFPIA MID3 WORKGROUP E F P I A,MARSHALL S F,BURGHAUS R,et al. Good practices in model-informed drug discovery and development:practice,application,and documentation[J]. CPT Pharmacometrics Syst Pharmacol,2016,5(3):93-122.
国家药品监督管理局药品审评中心.化学药物儿科人群药代动力学研究技术指导原则[EB/OL].(2013-12-25)[2023-08-04].https://www.cde.org.cn/main/news/viewInfoCommon/348abe615ecb413d4ed8a04cbd267bc0https://www.cde.org.cn/main/news/viewInfoCommon/348abe615ecb413d4ed8a04cbd267bc0.
Center for Drug Evaluation,NMPA. Technical guidelines for pharmacokinetic studies of chemical drugs in pediatric population[EB/OL]. (2013-12-25)[2023-08-04]. https://www.cde.org.cn/main/news/viewInfoCommon/348abe615- ecb413d4ed8a04cbd267bc0https://www.cde.org.cn/main/news/viewInfoCommon/348abe615-ecb413d4ed8a04cbd267bc0.
韩鸿璨,王骏,李栋,等. 模型引导的药物研发在儿科人群用药研究中的应用及策略[J]. 中国临床药理学杂志,2021,37(22):3193-3198.
HAN H C,WANG J,LI D,et al. The application and stra- tegies of model-informed drug development in pediatric drug studies[J]. Chin J Clin Pharmacol,2021,37(22):3193-3198.
李禄金,丁俊杰,刘东阳,等. 基于模型的荟萃分析一般考虑[J]. 中国临床药理学与治疗学,2020,25(11):1250-1267.
LI L J,DING J J,LIU D Y,et al. General considerations of model-based meta-analysis[J]. Chin J Clin Pharmacol Ther,2020,25(11):1250-1267.
GILL J,CETNAR J P,PRASAD V. A timeline of immune checkpoint inhibitor approvals in small cell lung cancer[J]. Trends Cancer,2020,6(9):736-738.
SUN Y L,HOU T,LIU S F,et al. Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects:study protocol for a randomized controlled trial[J]. Trials,2015,16(1):64.
李健,杨进波,王玉珠. 模型引导的药物开发在新药研发中的应用[J]. 中国临床药理学与治疗学,2020,25(1):1-8.
LI J,YANG J B,WANG Y Z. Applications of model-informed drug development (MIDD) on new drug research and development[J]. Chin J Clin Pharmacol Ther,2020,25(1):1-8.
WANG X,LEE W Y W,ZHOU X L,et al. A pharmacodynamic-pharmacokinetic (PD-PK) study on the effects of Danshen (Salvia miltiorrhiza) on mida- zolam,a model CYP3A probe substrate,in the rat[J]. Phytomedicine,2010,17(11):876-883.
FDA. Clinical drug interaction studies-study design,data analysis,and clinical implications guidance for industry,2017[EB/OL].(2017-10-25)[2023-08-04]. https://www.fda.gov/drugs/resources/clinical-drug-interaction-studieshttps://www.fda.gov/drugs/resources/clinical-drug-interaction-studies.
BUDHA N R,LEABMAN M,JIN J Y,et al. Modeling and simulation to support phase 2 dose selection for RG7652,a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9[J]. AAPS J,2015,17(4):881-890.
MANDEMA J W,SALINGER D H,BAUMGARTNER S W,et al. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis[J]. Clin Pharmacol Ther,2011,90(6):828-835.
CHAN P,PESKOV K,SONG X Y. Applications of model-based meta-analysis in drug development[J]. Pharm Res,2022,39(8):1761-1777.
李雪,王磊,卜睿臻,等. 基于模型引导的中药安全用药的研究策略:中药定量毒理学[J]. 中草药,2023,54(2):359-366.
LI X,WANG L,BU R Z,et al. Model-guided research strategies for safe use of traditional Chinese medicine:quantitative toxicology of traditional Chinese medicine[J]. Chin Tradit Herb Drugs,2023,54(2):359-366.
郑青山,陈凯先. 基于模型的中药研发[J]. 世界科学技术-中医药现代化,2018,20(8):1269-1278.
ZHENG Q S,CHEN K X. Model-based Chinese medicine development[J]. Mod Tradit Chin Med Mater Med-World Sci Technol,2018,20(8):1269-1278.
CHENG D,LI W J,WANG L J,et al. Pharmacokinetics,pharmacodynamics,and PKPD modeling of curcumin in regulating antioxidant and epigenetic gene expression in healthy human volunteers[J]. Mol Pharm,2019,16(5):1881-1889.
周惠芬,何昱,张宇燕,等. 川芎和黄芪有效部位组合给药后川芎嗪在脑缺血再灌注大鼠体内的PK-PD结合研究[J]. 中草药,2016,47(19):3463-3468.
ZHOU H F,HE Y,ZHANG Y Y,et al. Study on PK-PD combination of ligustrazine in cerebral ischemia reperfusion rats after ig administration of effective parts in compatibility of Chuanxiong Rhizoma and Astragali Radix[J]. Chin Tradit Herb Drugs,2016,47(19):3463-3468.
潘洁,王昌权,李奎,等. 基于大鼠类风湿性关节炎模型建立黑骨藤的PK-PD模型[J]. 中草药,2020,51(20):5194-5200.
PAN J,WANG C Q,LI K,et al. PK-PD model of Periploca forrestii based on rheumatiod arthritis rat model[J]. Chin Tradit Herb Drugs,2020,51(20):5194-5200.
谭兰芳,陈超,樊旭蕾,等. 基于PK-PD模型评价脑脉通保护神经细胞的药效物质研究[J]. 中国中药杂志,2019,44(12):2588-2593.
TAN L F,CHEN C,FAN X L,et al. Study on pharmacodynamic material basis of Naomaitong to protect neuronal cells based on PK-PD model[J]. China J Chin Mater Med,2019,44(12):2588-2593.
林力,刘建勋,张颖,等. 中药复方双参通冠方的PK/PD数据分析研究[J]. 世界科学技术-中医药现代化,2012,14(3):1583-1589.
LIN L,LIU J X,ZHANG Y,et al. A PK/PD data proces- sing study on Chinese formulation of Shuang-Shen-Tong-Guan prescription[J]. Mod Tradit Chin Med Mater Med-World Sci Technol,2012,14(3):1583-1589.
肖建鹏. 基于网络药理学和PK-PD结合模型阐释酒女贞子抗骨质疏松增效机理[D]. 镇江:江苏大学,2022.
XIAO J P. Synergistic mechanism of wine-processed Fructus Ligustri Lucidi against osteoporosis integrated network pharmacology and PK-PD model[D]. Zhenjiang: Jiangsu University,2022.
WANG T Y,LIN S,LI H,et al. A stepwise integrated multi-system to screen quality markers of Chinese classic prescription Qingzao jiufei decoction on the treatment of acute lung injury by combining ‘network pharmacology-metabolomics-PK/PD modeling’[J]. Phytomedicine,2020,78:153313.
毕聪,郑如文,黄海涛,等. 小柴胡颗粒基于网络药理学的组方配伍规律解析[J]. 药学研究,2020,39(9):504-513.
BI C,ZHENG R W,HUANG H T,et al. Network pharmacology based analysis of the formula rules of Xiaochaihu granules[J]. J Pharm Res,2020,39(9):504-513.
寇俊萍,禹志领,龚树强,等. 小承气汤、厚朴大黄汤及厚朴三物汤药理作用[J]. 中成药,2004,26(1):57-59.
KOU J P,YU Z L,GONG S Q,et al. The actions of Xiaochengqi decoction,Houpudahuang decoction and Houpusanwu decoction[J]. Chin Tradit Pat Med,2004,26(1):57-59.
李晓萌,苏布达,黄志伟,等. 基于生理药动学模型预测乌头碱在人体的药动学行为[J]. 中草药,2023,54(2):425-433.
LI X M,SU B D,HUANG Z W,et al. Predicting pharmacokinetic behavior of aconitine in humans based on phy-siological pharmacokinetic model[J]. Chin Tradit Herb Drugs,2023,54(2):425-433.
虞立. 养阴通脑颗粒主要有效部位配伍的药动学与药效学研究[D]. 杭州:浙江中医药大学,2016.
YU L. Study on PK and PD of compatibility of YTG prescription effective parts[D]. Hangzhou:Zhejiang Chinese Medical University,2016.
田瑶. 青藤碱关节腔局部PK-PD结合模型研究[D]. 广州:广州中医药大学,2012.
TIAN Y. Study on joint cavity local PK-PD modeling of sinomenine[D]. Guangzhou:Guangzhou University of Chinese Medicine,2012.
雒银珍,赵博文,陈茜,等. 基于分子模拟技术的豨莶通栓制剂调脂作用机制及剂型选择研究[J]. 中国中药杂志,2019,44(7):1436-1441.
LUO Y Z,ZHAO B W,CHEN X,et al. Lipid regulation mechanism and dosage form selection of Xixian tongshuan preparation based on molecular simulation methods[J]. China J Chin Mater Med,2019,44(7):1436-1441.
何宝峰,马新换,徐志伟,等. 基于改进熵权法联合TOPSIS模型和BPNN建模优化甘草糖类成分提取工艺[J]. 中国药学杂志,2023,58(8):675-682.
HE B F,MA X H,XU Z W,et al. Optimization of Glycyrrhiza sugar process based on improved entropy weight method combined with TOPSIS model and BPNN model[J]. Chin Pharm J,2023,58(8):675-682.
马青玉. 基于小样本的双频超声萃取工艺参数优化[D]. 北京:北京化工大学,2021.
MA Q Y. Process parameter optimization of dual-frequency ultrasound extraction based on small sample[D]. Beijing:Beijing University of Chemical Technology,2021.
戴胜云. 中药直接压片处方智能设计方法研究[D]. 北京:北京中医药大学,2019.
DAI S Y. Study on intelligent design method of direct compression prescription of traditional Chinese medicine[D].Beijing:Beijing University of Chinese Medicine,2019.
王学成,康超超,伍振峰,等. 基于Weibull函数的单颗六味地黄丸干燥过程模拟及其动力学分析[J]. 中国实验方剂学杂志,2019,25(12):133-139.
WANG X C,KANG C C,WU Z F,et al. Simulation of drying process of single Liuwei dihuangwan and analysis of its dynamics based on Weibull function[J]. Chin J Exp Tradit Med Formulae,2019,25(12):133-139.
崔世博. 中药提取工艺仿真系统测试案例的研究[D]. 北京:北京化工大学,2017.
CUI S B. Research on testing cases of Chinese medicine extraction process simulation system[D]. Beijing:Beijing University of Chemical Technology,2017.
杨明. 中药制剂工程学[M]. 北京:化学工业出版社,2018:172-193.
YANG M. Chinese medicine preparation engineering[M]. Beijing:Chemical Industry Press,2018:172-193.
LU T,YANG J L,GAO X M,et al. Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic pills,a cardiovascular herbal medicine[J]. Drug Metab Dispos,2008,36(8):1578-1586.
黄丽平,刘思佳,姚雅琦,等. 药动学-药效学(PK-PD)模型的研究方法及在中药领域中的优势与应用[J]. 中草药,2023,54(2):367-374.
HUANG L P,LIU S J,YAO Y Q,et al. Research methods of pharmacokinetics-pharmacodynamics (PK-PD) model and its advantages and application in traditional Chinese medicines[J]. Chin Tradit Herb Drugs,2023,54(2):367-374.
龚小红. 基于整合药动学/药效学方法研究大黄附子配伍治疗阳虚便秘的增效减毒作用[D]. 成都:成都中医药大学,2017.
GONG X H. Study on synergistic and attenuated of compatibility of Rhubarb and Aconite in Yang deficiency consti- pation model rats by methods of integrative pharmacokinetics/pharmacodynamics[D]. Chengdu:Chengdu University of TCM,2017.
LI S Z,YU Y Q,BIAN X L,et al. Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling[J]. Arch Toxicol,2021,95(5):1683-1701.
FDA. Model-informed drug development pilot program [EB/OL].(2020-08-20)[2023-08-31]. https://www.fda.gov/newsevents/pressreleases/ucm294657https://www.fda.gov/newsevents/pressreleases/ucm294657.
MADABUSHI R,BENJAMIN J M,GREWAL R,et al. The US food and drug administration’s model-informed drug development paired meeting pilot program:early experience and impact[J]. Clin Pharmacol Ther,2019,106(1):74-78.
李认书,朱永宏,孙鹤. 定量药理学在美国FDA药品审批决策中的应用[J]. 中草药,2010,41(12):2095-2098.
LI R S,ZHU Y H,SUN H. Application of pharmacome- trics on drug approval decision in FDA of USA[J]. Chin Tradit Herb Drugs,2010,41(12):2095-2098.
0
Views
10
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution